Menu
RxSight® is an ophthalmic medical technology corporation headquartered in Aliso Viejo, California that has commercialized the Light Adjustable Lens™ (LAL®/LAL+™), the world’s first and only adjustable intraocular lens (IOL) that is customized after cataract surgery. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye.
Dr. Kurtz is the President and Chief Executive Officer of RxSight, having joined the company in June 2015. From 2010 to 2015, Dr. Kurtz was Vice President, General Manager of Alcon LenSx. He was previously co-founder, President and CEO of LenSx Lasers from 2008 until its acquisition by Alcon in 2010, and of IntraLase Corp. from 1997 to 1999. He continued at IntraLase in the role of Vice President, Medical Director from 1999 to 2005.
A board-certified ophthalmologist and retina specialist, Dr. Kurtz was a Professor of Clinical Ophthalmology at the University of California, Irvine from 2000 through 2014. From 1995 to 2000, he was an Assistant Professor of Ophthalmology at the University of Michigan. Dr. Kurtz serves on the Board of Allegro Ophthalmics, Inc.
Dr. Kurtz received a Bachelor of Arts degree with honors in Biochemistry from Harvard College and his Doctor of Medicine (MD) degree from the University of California, San Diego.
Eric joined RxSight in June 2015 as the company’s Chief Commercial Officer. Prior to this position, he was a co-founder of LenSx Lasers and served as Chief Commercial Officer from 2008-2010, until the company was acquired by Alcon in 2010. He went on to serve as Vice President of Surgical Development at Alcon LenSx until 2014. He joined Intralase Corp. in 1999 and served as SVP Global Marketing until the company was acquired by AMO (Advanced Medical Optics) in February 2007. In 1993, he joined Chiron Vision (acquired by Bausch & Lomb in October 1997), leading the company’s refractive surgery division as Global Director of Refractive Surgery until 1999. Mr. Weinberg began his career in medical devices at Steinway Instruments in 1980, where he was involved in the development and commercialization of multiple refractive surgery technologies, including the microkeratome.
Ilya serves as Chief Operating Officer for RxSight, having joined the company in September 2015. Prior to joining RxSight, Ilya held a variety of positions of increasing responsibility at Alcon LenSx. He started as a Senior Laser Scientist in 2008 at LenSx Lasers and progressed to Director of Optical & Imaging Systems after LenSx was acquired by Alcon in 2011. At Alcon LenSx, Ilya led a multidisciplinary team in the development of laser ophthalmic systems until joining RxSight in 2015. Previously, Ilya was a Laser Scientist conducting femtosecond laser research at the University of California, Irvine from 2003 to 2008.
Ilya received a Bachelor’s degree with honors in Physics and a Master’s degree with honors in Physics and Engineering from the Moscow Institute of Physics & Technology and a Ph.D. in Physics from the Institute of Chemical Physics, Russian Academy of Sciences.
Shelley has served as Chief Financial Officer of RxSight since January 2016. Prior to joining RxSight, she was Chief Financial Officer at Endologix, a cardiovascular medical device company, from 2013 to 2015. She served as Chief Financial Officer at LenSx Lasers from 2008 until the company was acquired by Alcon in 2010, continuing as the Associate General Manager at Alcon LenSx until 2013. Previously, she served as Chief Financial Officer at Therox, Inc., a medical device company, from 2007 to 2009, and at Intralase Corp. as the Executive Vice President and Chief Financial Officer from 2001 to 2007. She currently serves on the board and as audit committee chairperson of Surface Ophthalmics, Inc.
Shelley earned a Bachelor of Arts degree in Economics with honors and a Master of Business Administration (MBA) degree with honors from the University of California, Irvine.
Patrick joined RxSight as Vice President of Quality in October 2015. In February 2022, he left to serve as Vice President of Product Quality at Intuitive Surgical. One year later, he rejoined RxSight as the Senior Vice President of Quality.
Prior to RxSight, Patrick held a variety of quality management positions of increasing responsibility including Director of Quality Assurance for Alcon (Novartis) where he planned and executed projects for quality improvement, integration, and remediation of quality and compliance efforts and Director of Quality Engineering for Saint Jude Medical where his efforts led to the innovation of new products resulting in 20 invention disclosures, over 15 patent submissions, and 10 patents.
Patrick earned a Bachelor of Science degree in Mechanical Engineering from the University of Houston in Houston, Texas and a Master of Science degree in Biomedical Engineering from the University of Texas Southwestern Medical School and University of Texas at Arlington.
Debe joined RxSight in January 2016 and is Vice President of Regulatory Affairs. For the previous 30 years, Debe served as a Consultant for US and International Regulatory Affairs activities in support of investigational (clinical) and registration (marketing) applications for a wide variety of ophthalmic devices and products. Debe began her career in Regulatory Affairs at Chiron Corporation in 1993.
Debe holds a Bachelor of Science degree in Business Administration and International Management from California Polytechnic University in San Luis Obispo, California.
Jeremy joined RxSight in October 2015 and now serves as Vice President of Engineering. He started his career in the research and development of ophthalmology devices as a Mechanical Engineer at LenSx Lasers in 2009, which was acquired by Alcon in 2010. He went on to serve as Senior Mechanical Engineer at Alcon LenSx until joining RxSight.
Jeremy earned both a Bachelor of Science degree and a Master of Science degree in Biomedical Engineering from the University of California, Irvine.
With over 30 years of sales experience in ophthalmology, Steve joined RxSight in August 2021 as Vice President of US Sales. Prior to this position, he was Area Vice President, Surgical Sales Western US with Johnson & Johnson Surgical Vision. Steve began his ophthalmology sales career at Allergan Pharmaceuticals in 1989 as Senior Territory Manager and became Senior Surgical Equipment Specialist from 1999 to 2006, during which time the company was spun-off as a stand-alone company named AMO (Advanced Medical Optics). Steve held roles of increasing responsibility in refractive sales with AMO, continuing through the acquisition of AMO by Abbott in 2009. In 2014, Steve was promoted to Director of US Refractive Sales of Abbott Medical Optics prior to their acquisition by Johnson & Johnson in 2017.
Steve holds a Bachelor of Arts degree with honors in Biology from Lawrence University in Appleton, Wisconsin.
Roy is Vice President of Marketing for RxSight, having joined the company in October 2016.
In the decade prior to joining RxSight, Roy played key marketing executive roles in four successful ophthalmic medical device start-up companies. This includes Director of Marketing for AquaSys, Inc. (acquired by Allergan), Associate Director of Clinical Product Management at LenSx Lasers (acquired by Alcon), Director of Marketing Applications at Wavetec Vision Systems (acquired by Alcon), and Global Associate Product Manager at IntraLase Corp. (acquired by Advanced Medical Optics). Roy began his career in the ophthalmic medical device industry as a market research analyst at Market Scope in 2003.
Roy earned a Bachelor of Arts degree with honors in Psychology from California State University, Fullerton.
Scott joined RxSight in November 2015 as Senior Vice President of Commercial Operations & Business Process and is Certified in Production and Inventory Management. From 2010 until he joined RxSight, Scott served as Director of Technical Support & Business Systems at Alcon LenSx (Novartis), where he supported the global launch of two first-in-market ophthalmology products. He joined IntraLase Corp. in 2001, where he held a variety of logistics and planning positions of increasing responsibility until 2006, when he joined AMO (Advanced Medical Optics) as Director of Materials Management. Scott began his career at Quest Diagnostics in 1992.
Jeff joined RxSight in 2009 and currently serves as Vice President of Clinical Affairs, where he is responsible for LAL clinical research and clinical affairs. Jeff began his career as an optometrist in 2004 at EYEXAM 2000 of California and Firstsight Vision Services, where he provided primary care optometric services.
Jeff earned a Bachelor of Science degree in Biochemistry from the University of California, San Diego and a Doctor of Optometry (OD) degree from the University of California, Berkeley School of Optometry.
Matt has over 30 years of research and development experience in medical technologies, with 35 issued patents. Matt joined RxSight in May 2013 and serves as the company’s Chief Technology Officer. Previously, he was Senior Program Director at Medtronic from 2011 to 2013. Prior to this position, Matt was Vice President of Research & Development for Advanced Bionics/Boston Scientific, where he was responsible for the only US-based cochlear implant. During his 11-year tenure at Boston Scientific, Matt held roles of increasing responsibility and performed all aspects of program and engineering management. Before that, Matt was a System Engineer and R&D Manager at Acuson Corporation, an ultrasonic imaging company.
Matt earned a Bachelor of Science degree in Electrical Engineering from the University of California, San Diego and a Master of Science degree and a Ph.D. in Electrical Engineering from Stanford University.
Oliver Moravcevic assumed the role of Vice President of Investor Relations at RxSight in November 2023, bringing over a decade of experience in the medical device industry. Prior to joining RxSight, Oliver served as the Director of Investor Relations at Edwards Lifesciences, where he showcased expertise in financial modeling, shareholder engagement, and strategic communication. Preceding his role in Investor Relations, Oliver held several finance positions, including corporate FP&A, business unit finance and treasury. Before his venture into the medical device sector, Oliver accumulated valuable experience in private equity and market research at Pathway Capital Management.
Oliver holds a Bachelor of Science degree in Business Administration from the University of California, Irvine – The Paul Merage School of Business.
Maureen has over 30 years of experience in medical device regulatory affairs and clinical study management. She joined RxSight in January 2016 and serves as Senior Vice President of Clinical & Regulatory Affairs. Maureen founded O’Connell Regulatory Consultants in 1997, a consulting firm specializing in strategic planning, preparation and administration of premarket device submissions and associated clinical trials. Prior to that, she worked in executive regulatory and clinical roles for Summit Technology, Inc., a laser products company, from 1988 to 1997.
Maureen earned a Bachelor of Science degree in General Management (Finance concentration) from Boston College.
An award-winning polymer chemist, Victoria Piunova joined RxSight as Vice President of LAL Chemistry in April 2022. Victoria brings over 10 years of experience in development of materials for biotechnology, sensing, and materials discovery. Victoria earned her Ph.D. in polymer Chemistry/Materials Science from the University of Southern California and did her postdoctoral training at the California Institute of Technology in Prof. Robert Grubbs’ group, where she collaborated with RxSight on the development of UV-absorbers for intraocular lenses. Victoria continued her independent career as a research staff member at IBM Almaden Research Center, where she earned a prestigious IBM Master Inventor title and led programs on development of polymer-based drug delivery vehicles and antimicrobial polymers for application in agriculture. Victoria is a recipient of Young Investigator Award (2018) and Young Industrial Polymer Scientist Award (2021) from American Chemical Society.
Victoria earned a Bachelor of Science degree in Chemistry from Leibniz Universitat Hannover in Germany and a Master of Science degree in Photochemistry/Photobiology from Bowling Green State University in Ohio.
Chris serves as Vice President of Intraocular Lens Development at RxSight. As Founding Scientist of RxSight (formerly Calhoun Vision, Inc.) in 2000, Chris helped develop both the Light Adjustable Lens (LAL) and Light Delivery Device technologies from concept to commercial release. Chris holds 22 patents for the LAL technology and has authored numerous publications.
Chris obtained his Ph.D. from the University of Nebraska-Lincoln in 1998 and was a Post-Doctoral Scholar for Professor Julia Kornfield at the California Institute of Technology from 1998 to 2000.
With over 30 years of experience as an Industrial/Manufacturing Engineer within the medical and ophthalmology fields, John joined RxSight in April 2018 as a Senior Director and was promoted to Vice President of Operations in 2021. Prior to that, John was Director of Manufacturing at LenSx, overseeing production of its laser device along with the Manufacturing Engineering group starting in 2009 through 2018, which included the acquisition of LenSx by Alcon. Previously, he was Manager of Systems Production at AMO (Advanced Medical Optics). He joined IntraLase Corp. in 2000 as a Senior Manufacturing Engineer and was serving as Director of Systems Production when the company was acquired by AMO in 2007. John began his career as an Industrial Engineer in the medical field in 1985 with Baxter and was Manager of Manufacturing for the Nichol’s Institute from 1997 to 2000.
John holds a Bachelor of Science degree in Industrial Engineering from the University of Illinois in Champaign, Illinois and is a Registered Professional Engineer. He also received a Master of Business Administration (MBA) degree from California State University in Long Beach, California.
Caroline is Vice President of Human Resources for RxSight, having joined the company in August 2015. Previously, she served as Human Resources Manager for LenSx Lasers starting in 2008 and continued in this position when the company was acquired by Alcon (Novartis) in 2010. She also served as Human Resources Manager from 1994 to 2001 at Total Access, a wireless communications company, and Senior Executive Assistant positions with the Swiss government and IntraLase Corp. With over 16 years of experience in the ophthalmic industry, Caroline is a passionate and experienced human resources leader with a proven history of successfully and strategically partnering with senior management to achieve organizational goals.
Caroline holds both a Bachelor of Business Administration degree in Human Resources and a Master of Business Administration (MBA) degree in Organizational Leadership from Brandman University (part of Chapman University) in Irvine, California.
Rebecca, who has held lead accounting roles in the medical device industry since 2000, joined RxSight in February 2017 as Director of Finance & Accounting. Earlier in her career, she became a licensed CPA during her tenure with Ernst & Young LLP. Since then, she has held various positions of increasing responsibility in accounting and finance with companies such as Disney, IntraLase Corp. (acquired by Advanced Medical Optics, Inc.), LenSx Lasers, Inc. (acquired by Alcon), and ReShape Medical (now ReShape Lifesciences).
Rebecca holds a Bachelor of Science degree with honors in Business Administration from Michigan Technological University in Houghton, Michigan and a CPA license (inactive) from the State of Michigan.
Approved use: The Light Adjustable Lens™ (LAL®), Light Adjustable Lens+™ (LAL+™), and Light Delivery Device™ (LDD™) system is approved for patients who have a cataract and need surgery for it, have corneal astigmatism (at least 0.75 diopters) before surgery, and do not have preexisting macular disease.
Who should not receive this treatment? The LAL/LAL+ and LDD system should not be used if you are taking medications that may increase your sensitivity to ultraviolet (UV) light; if you are taking a medication that is considered harmful to your retina; if you have a history of herpes eye infection or uncontrollable eye movements (nystagmus); or if you are unable to comply with your doctor’s schedule of LDD light treatments and instructions for wearing special UV-protective glasses for several weeks following cataract surgery.
What warnings should I be aware of? Preexisting macular disease and certain eye conditions may increase the risk of complications. Your doctor will determine if you are a good candidate for the LAL/LAL+. If you have any complications during your cataract surgery before the LAL/LAL+ is implanted, you may need to have another intraocular lens (IOL) implanted instead of the LAL/LAL+.
What precautions should I be aware of? The safety and effectiveness of the LAL and LDD have not been established in patients with certain preexisting eye conditions or in patients who experience certain complications during cataract surgery. The safety and effectiveness of the LAL+ has not been substantiated in clinical trials. The effect of the LAL+ optical design on quality of vision, contrast sensitivity, and subjective visual disturbances have not been evaluated clinically. You should discuss these issues with your doctor.
Following surgery, you must wear the special UV-protective glasses during all waking hours for about 4 to 5 weeks and comply with your doctor’s schedule of LDD light treatments. Failure to wear the UV-protective glasses can result in an unpredicted vision change or loss of vision quality after exposure to UV light, such as from sunlight. This may require a second surgery to remove the LAL/LAL+ from your eye and replace it with another IOL.
What are the potential risks? As with any surgical procedure, there are risks associated with cataract surgery and IOL implantation. Please discuss these risks with your doctor. Potential risks associated with LDD light treatments include mild alterations to color perceptions; temporary scratchiness, irritation, or dryness to the front part of your eye; and activation of a previously undiagnosed herpes eye infection. Longer lasting and serious adverse events related to the UV light exposure are possible, but rare. There is a small chance that your vision could be made worse or that you may require additional surgery as a result of a complication.
Caution: Federal law restricts this device to sale by or on the order of a physician.
©2024 RxSIGHT. All Rights Reserved. COM-1043 Rev. C
The LAL provides optimized vision for patient satisfaction.2
LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).
Since the LAL is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.
The LAL offers LASIK-like accuracy in cataract surgery.2,3
92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).
Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.
The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.
The Light Adjustable Lens corrects down to 0.5 diopters of astigmatism, which is the lowest level approved to be treated.
